

**Supplemental Table 2. Adjudication of Discrepancies in Readings for Radiographic and MRI Efficacy Endpoints**

<b>Endpoint</b>	<b>Placebo</b>	<b>Lutikizumab</b>
Verbruggen-Veys both hands*	24/67 (35.8)	19/64 (29.7)
Kellgren-Lawrence score, both hands	0/67	0/64
OARSI JSN, both hands	0/67	0/64
OARSI osteophytes, both hands	0/67	0/64
HOAMRIS synovitis, index hand	4/63 (6.3)	5/59 (8.5)
HOAMRIS erosive damage, index hand	4/63 (6.3)	4/59 (6.8)
HOAMRIS BML, index hand	5/63 (7.9)	3/59 (5.1)
HOAMRIS cartilage space loss, index hand	0/63	4/59 (6.8)

BML=bone marrow lesions; HOAMRIS=Hand Osteoarthritis Magnetic Resonance Scoring system; N=total number of subjects with  $\geq 1$  non-missing image at baseline; OARSI=Osteoarthritis Research Society International.

\*Verbruggen-Veys scores were adjudicated whenever the change in Ghent University Score System results (data not shown) had a difference between readers of at least 50 points for any joint.